Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

"There's no specific treatment for an RSV infection," the NHS explains. "It often gets better on its own in one or two weeks ...

The bivalent respiratory syncytial virus prefusion F vaccine is highly effective and well tolerated against RSV-associated ...

The respiratory syncytial virus (RSV) infects cells along the human respiratory tract, from the nose to the lungs. Each year ...

Historically, RSV has been studied mainly in infants and older adults, but recent research shows that it also poses a ...

Among older adults in Spain, hospitalisation rates from respiratory syncytial virus (RSV) infection increases progressively ...

A single dose of respiratory syncytial virus vaccine was effective against infections and associated hospitalizations in veterans aged at least 60 years during the 2023-24 season.

RSV leads to approximately 1.4 million hospitalizations and over 13,000 in-hospital deaths worldwide among infants under six ...

Population-based analyses of new vaccination programmes provide robust real-world evidence for post-licensure vaccine evaluation. A 2023–24 vaccine effectiveness analysis of immunocompetent adults ...

New data from the Centers for Disease Control and Prevention suggest Georgia could see a rise in COVID-19 cases in the coming ...

Abrysvo, which is now the first maternal RSV vaccine to be prequalified by the organisation, aims to prevent RSV-associated ...

In primary care settings, the burden of RSV on young children and their guardians often varied between the countries of ...